newsletter

VOL.43 / 2023.12.11

국내외 결핵(TB)뉴스

STOP-TB 한국사무국 소식

The World Health Organization released two new guidance documents to assist national TB programs and other stakeholders in adopting and implementing next generation sequencing for the detection of drug-resistant TB.

The Stop TB Partnership’s TB REACH initiative launched its Wave 11 round of funding focused on innovative and people-centered approaches for integrated services for TB and other diseases at the primary and community levels of health systems. The deadline for applications is 17 January 2024. Access the full announcement here.

As part of UNITE4TB and the COMET initiative, an international survey seeks to determine the most important outcomes to measure in Phase 3 trials of pulmonary TB treatment. It aims to collect the perspectives of TB researchers, healthcare workers, survivors and carers from a range of countries. The survey is available here. Download a flyer here.

Médecins Sans Frontières released a report offering case studies of two critical TB tools, GeneXpert and delamanid, and outlining actions that the corporations making them, Cepheid/Danaher and Otsuka, respectively, need to take to unlock access to these revolutionary, lifesaving medical tools.

A combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, has the potential to become a 'universal TB regimen', shortening and improving treatment for both drug-sensitive and drug-resistant TB.

Treatment Action Group (TAG) released the 2023 Tuberculosis Diagnostics Pipeline Report, giving a detailed overview of the TB diagnostics pipeline, noting it is healthier and more diverse than it has ever been, with dozens of new tests in the pipeline showing potential to deliver fast, accurate, affordable testing using samples that all people can easily provide.

endTB clinical trial offers multiple new shortened drug regimens to treat adults and children with multidrug–resistant TB.

A collaborative study, published in Nature Communications, uncovered that elevated glycerol levels are responsible for increased severity of TB disease in experimental models with type 2 diabetes.

In a paper, published in The Journal of Infectious Diseases, scientists reported a promising new approach, the Bacillus Calmette-Guérin (BCG) vaccine human challenge model, to speed vaccine testing for TB.

A study, published in Nature Communications, showed how Mycobacterium tuberculosis perturbs homeostasis of the high-energy molecule NADH and reprograms glycolysis in myeloid cells. This highlights glycolysis as a potential therapeutic target to combat TB.

A promising new cancer therapy also appears extremely potent against TB. Scientists found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant. The findings, reported in Biomedicine & Pharmacotherapy, were made in novel cellular models featuring TB-infected human cells that can help accelerate screening of potential TB drugs and therapies like this one.

RESIST-TB released its December 2023 newsletter with the latest updates and research publications on drug-resistant TB.